Exclusive eBook: Inside the stealthy startup that pitched brainless human clones
On April 30th, MIT Technology Review published an exclusive eBook built around one of the stranger documents in recent biotech history: a pitch, delivered by a stealthy startup to investors, proposing the commercial creation of brainless human clones. Strip away the science fiction associations and sit with what that sentence actually describes. People in a room. A slide deck, presumably. A founder explaining, in the language of market opportunity and addressable need, why harvesting organs or biological material from cloned human bodies without brains represented a viable business. The investors in those rooms had to absorb that, and then make a decision. MIT Technology Review, for its part, decided the story was worth an eBook — not a blog post, not a paragraph buried in a roundup, but a dedicated long-form product. The startup's full identity, its founders, and the precise trajectory of the pitch remain partly shrouded, which is either responsible sourcing practice or a detail that will matter enormously when the fuller picture emerges.
If confirmed, here is what this means. The regulatory and ethical architecture governing human biological material was not designed for this conversation, and the fact that it reached investor pitches before reaching any public oversight body is itself the story within the story. Biotech investment culture has a well-documented tolerance for ideas that sit uncomfortably close to lines most people assume are uncrossable — but this would represent a different category of crossing. The second-order effect is institutional: every serious biotech investor now has to consider that their due diligence process needs a filter for proposals that are not merely risky or premature, but that raise questions about the legal personhood of the thing being created. Regulators in the EU, the UK, and the US will be watching each other to see who blinks first into a formal response. The startup's anonymity buys it time, but not indefinitely.
Watch for the startup's identity to surface — either through investigative follow-up or legal filings — and for any indication of how far the pitch traveled before it stopped. Whether it found funding changes everything about how urgent the policy response needs to be.
After operating in secrecy for years, a startup company called R3 Bio, in Richmond, California, suddenly shared details about its work last week—saying it had raised money to
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Inside the stealthy startup
NewsHive monitors these sources continuously. All signal titles above link to the original reporting.
Intelligence by NewsHive. Need help navigating what this means for your business? Contact GeekyBee →